This study is looking at the safety and tolerability of a drug called HRX215 in adults aged 18 to 75 who have had liver surgery (liver resection) for colorectal cancer that has spread to the liver (colorectal carcinoma liver metastases). Researchers want to see if HRX215 is safe and how your body handles it. You would take HRX215 capsules or a placebo (an inactive substance that looks like the drug) twice a day for 28 days. The study will measure any side effects you experience for up to 6 months and check HRX215 levels in your blood for 28 days. The study aims to enroll 80 participants, but its current status is unclear.

Study design

This is an interventional study comparing HRX215 to a placebo. It plans to enroll 80 participants.

What's involved

You would take HRX215 or placebo twice daily for 28 days. This includes daily visits for the first 7 days, then clinic visits every two weeks for the next two visits, and additional visits at 3 and 6 months.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for adverse events for 6 months after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.